Theolytics-preview

Theolytics

Private

OxfordHealthcare & Life Scienceshttps://www.theolytics.com/

Last Round

Grant

Mar 4, 2026

Total Funding Raised

$14.31M

Company Overview

Theolytics is a biotechnology company that operates a phenotypic screening platform intended to harness viruses to combat cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

oncolytic viral therapyoncolytic virusoncolytic immunotherapyadenovirus platformcancer-killing virusovarian cancer treatmentdrug discovery platformphenotypic screeningcancer-associated fibroblastsCAFstumor microenvironmentTMEclinical-stage biotechstromal-rich tumorscolorectal cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Theolytics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Theolytics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Mar 4, 2026
Grant	Sep 2, 2024
VC Round	Apr 17, 2024
Grant	Jun 1, 2022
Series A	Jan 7, 2021
Grant	Nov 6, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Margaret Duffy

Co-Founder And Chief Scientific Officer

Founding Team

Theolytics Investors

Notable investors and investment history

Investor	Rounds
Innovate UK	Grant
UK Research and Innovation	Grant
Epidarex Capital	VC Round, Series A
Oxford Science Enterprises	VC Round, Series A, Seed
Taiho Ventures	VC Round, Series A
Horizon Europe	Grant
University of Oxford	VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 4, 2026
$9.3M raised in a grant round.
Oct 1, 2025
Matilde Saggese, MD, appointed as new CMO.

View all signals

Theolytics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Theolytics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Theolytics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford

Employee Range32

Year Founded2017

Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.